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ADAM = a disintegrin and metalloprotease; CBF1 = Cp binding factor 1; CSL = CBF1, Suppressor of Hairless, Lag-1; DSL = Delta, Serrate,
Lag-2; HGF = hepatocyte growth factor; HPV = human papillomavirus; Lag = lin-12 and glp-1; NICD = Notch intracellular domain; TGF-β = trans-
forming growth factor beta.
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Introduction
Notch genes encode large transmembrane proteins that
act as receptors for the Delta, Serrate, Lag-2 (DSL) family
of ligands (Fig.1a) [1]. There are four different Notch pro-
teins in mammals and five known ligands: Delta-like 1,
Delta-like 3 and Delta-like 4, and Jagged 1 and Jagged 2
[2–6]. Notch proteins are highly conserved, and they play
crucial roles in cell fate decisions during the development
of organisms as diverse as humans and sea urchins [7]. In
addition, aberrant Notch signalling is associated with
several human diseases. These include the autosomal
dominant developmental disorder Alagille’s syndrome, the
neural degenerative disease CADASIL (cerebral auto-
somal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy), and several cancers [8].
Experiments in Drosophila, Caenorhabditis elegans, and
mammalian cell lines have provided a detailed model for
DSL signalling via Notch receptors (Fig.1b) (reviewed in
[1,9]). The signal is initiated by the interaction of DSL
ligands with the extracellular domain of Notch molecules
on the surface of neighbouring cells. This leads to two
proteolytic cleavages, one outside and one within the
transmembrane domain, which release the Notch intracel-
lular domain (NICD). The extracellular cleavage event is
catalysed by an ADAM protease (a disintegrin and
metalloprotease), while the intramembrane cleavage is
mediated by a complex containing Presenilin and Nicas-
trin. The released NICD fragment then enters the nucleus,
where it interacts with members of the CBF1, Suppressor
of Hairless, Lag-2 (CSL) family of transcription factors.
This interaction converts the CSL proteins from transcrip-
tional repressors to transcriptional activators, and thus
leads to elevated expression of specific genes. Several
such target genes have been identified in mammals
including  Hes1 and  Hes5, members of the Hairy and
Enhancer of Split family of basic helix–loop–helix trans-
cription factors [10,11].
While the mechanism of DSL Notch signalling via CSL
factors has been extensively documented in a variety of
biological settings, recent research indicates that Notch
proteins can also signal via an alternative intracellular
pathway. This pathway, which requires the cytoplasmic
protein Deltex, appears to prevent cell differentiation.
Although there are data that suggest a similar pathway may
exist in mammals [12,13], it has so far been described only
in Drosophila (Fig.1c) (reviewed in [14]). With the excep-
Aberrant Notch signalling has been observed in several human cancers, including acute T-cell
lymphoblastic leukaemia and cervical cancer, and is strongly implicated in tumourigenesis. Unregulated
Notch signalling in the mouse mammary gland leads to tumour formation. These results raise the
possibility that Notch signalling might play a role in human breast cancer. There are currently few
reports that address this question directly and this appears to be an area worthy of further
investigation.
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tion of Deltex, the intracellular proteins required for this
alternative pathway are currently unclear. It has been sug-
gested, however, that signalling through this pathway may
inhibit Jun N-terminal kinase signalling [15] or sequester
the transcriptional coactivator CREB binding protein
(CBP)/p300 [16]. Importantly, the domains of Notch
required for this pathway are not the same as those
needed for Notch signalling via CSL family members
(Fig.1c) [17,18]. Recent experiments also suggest that
Notch signalling via the Deltex-dependent pathway sup-
presses the expression of Wnt target genes [19,20], and
that crosstalk between the two pathways inhibits Notch
signalling via this pathway [18]. This crosstalk is likely to
occur at the cell surface through interactions between
either Notch and Wnt proteins themselves, or between
Notch and Dishevelled (reviewed in [14]).
Perhaps the best understood biological role of Notch sig-
nalling is in the conserved developmental process of
lateral inhibition (Fig.2a) [21,22]. For example, in both
Drosophila and vertebrate embryogenesis, lateral inhibi-
tion is responsible for limiting the number of cells that will
adopt a neural fate [23–27]. In both cases, neural devel-
opment is initiated within small groups of cells. In each of
these groups, however, only one or two cells will maintain
their neural fate. As these cells differentiate, they produce
an inhibitory signal that prevents their neighbours from
also adopting the neural fate. It is the DSL/Notch/CSL sig-
nalling pathway that transduces this inhibitory signal. In
addition, Notch signalling has been shown to play an
important role in defining the two different cell fates that
result from asymmetric cell divisions, and in inductive sig-
nalling events that cause cells to adopt a specialised cell
fate at the boundary between two cell populations
(reviewed in [22]) (Fig.2b,c).
Notch signalling in human cancer
As with several other signalling pathways, aberrant Notch
signalling has been observed in a number of human
cancers, suggesting a possible role of Notch signalling in
tumour formation. Moreover, the Notch1 gene was first
identified in humans as a locus disrupted in a subset of
T-cell acute lymphoblastic leukaemias by the
(7;9)(q34;q34.3) chromosomal translocation characteris-
tic of such tumours [28]. This rearrangement leads to
expression of a Notch1 protein comprising the transmem-
brane and intracellular domains only. Similar Notch pro-
teins have been shown to undergo spontaneous cleavage
within the transmembrane domain in a ligand-independent
manner, and hence to activate the Notch signalling
pathway constitutively in experimental assays [1]. These
data provide strong circumstantial evidence that unregu-
lated Notch signalling contributes to tumour development.
This contribution to tumour development has been tested
directly in two different mouse models in which a constitu-
tively active Notch1 protein was expressed, either in
T cells under the control of the lck promoter [29] or, more
generally, in bone marrow cells [30]. The mice developed
T-cell lymphomas in both cases. This observation strongly
argues that uncontrolled Notch signalling is responsible
for the development of T-cell acute lymphoblastic
Figure 1
Pictorial representation of a Notch protein and its signalling pathways.
(a) The extracellular domain of Notch contains between 29 and 36
tandemly repeated epidermal growth factor (EGF)-like repeats, some
of which are required for the interaction of Notch with its ligands, along
with three Lin-12/Notch repeats. The most prominent motifs in the
intracellular domain are six cdc10/ankyrin repeats and a PEST domain
close to the C-terminus of the protein. The intracellular domain also
contains two functionally defined domains: the juxtamembrane RAM23
domain that mediates the interaction of the intracellular domain of
Notch with CBF1, Suppressor of Hairless, Lag-1 (CSL) proteins; and a
transcriptional activation domain that is C-terminal to the
cdc10/ankyrin repeats. (b) The interaction of Delta, Serrate, Lag-2
(DSL) ligands (black) with EGF-like repeats 11 and 12 of Notch (dark
blue and yellow) leads to two proteolytic cleavages, one extracellularly
and one within the membrane, which release the intracellular domain of
Notch (NICD). This fragment of Notch then migrates to the nucleus
(dotted line) where it interacts with CSL proteins (orange) via its
RAM23 domain to form a transcriptional activator. (c) Recent
experiments have suggested that Notch can signal through a second
distinct signalling pathway that requires the cytoplasmic protein Deltex
(light blue). Deltex has been shown to interact directly with the
cdc10/ankyrin repeats of Notch, and signalling through this pathway
has been proposed to both inhibit Jun N-terminal kinase (JNK)
signalling and to sequester the transcriptional coactivator CREB
binding protein (CBP)/p300. It is not currently known whether
signalling through this pathway is an intrinsic property of Notch
proteins or whether it is activated by a ligand (green). It has been
shown, however, that Wnt signalling can regulate this pathway and
that this regulation requires both EGF-like repeats 17–19 and 24–26,
and the region C-terminal to the cdc10/ankyrin repeats.71
leukaemia in human patients carrying the (7;9)(q34;q34.3)
translocation. Activating Notch signalling by overexpress-
ing the DSL ligand Delta-like 4 [31], or expressing trun-
cated forms of Notch3 [32], also leads to T-cell
lymphomas in mice. Moreover, only those forms of Notch1
protein that are able to activate a CSL-dependent reporter
gene are able to induce T-cell leukaemia. This suggests
that the leukaemias arise from excessive CSL-dependent
signalling in T cells [33]. Similar conclusions about CSL-
dependent signalling were reached in an analysis of
epithelial cell transformation by Notch1 and E1A in rat
kidney epithelial cells [34].
Activation of Notch signalling has also been observed in
retrovirus-induced T-cell lymphomas in both mice and cats
[35–39]. In the mouse models, retroviral proviruses are
found inserted in the Notch1 locus just upstream of the
exon encoding the transmembrane domain. This leads to
expression of a novel cDNA that encodes the transmem-
brane and intracellular domains of Notch only. In cats, a
subset of lymphomas that arise after feline leukaemia virus
infection is caused by viruses that have acquired a Notch2
cDNA encoding a similar N-terminally truncated protein. In
both cases, therefore, an activated Notch protein is
expressed of the sort predicted to signal constitutively via
CSL proteins.
In two of the aforementioned studies of T-cell lymphomas,
a second class of retroviral insertions within the Notch1
gene has been described [38,39]. These insertions occur
within the 3′ region of the coding sequence and result in
truncated proteins lacking the region C-terminal to the
cdc10/ankyrin repeats (see Fig.1). These deletions
remove a PEST domain at the very C-terminus of Notch1
and are expected to increase the stability of the NICD
fragment generated in response to DSL signalling. This
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Figure 2
Roles of Notch signalling during development. (a) The best known role of Notch in development is in a process known as lateral inhibition. This is a
conserved developmental mechanism by which a particular fate (navy blue cell) is adopted by one or two cells from a larger group that all have the
potential to adopt the fate (mid-blue cells). As the selected cells adopt their fate (represented by the darkening of the shade of blue), they emit an
inhibitory signal that prevents neighbouring cells from adopting the same fate (represented by lightening of the blue shade until it is white). The
DSL/Notch/CSL signalling pathway transduces the lateral inhibition signal. (b) In addition to its role in lateral inhibition, CSL-dependent Notch
signalling also plays an important role in defining the two cell fates that arise from an asymmetric cell division. Typically, the inheritance of the Numb
protein (green) within one of the two daughter cells inhibits Notch signalling within that cell. As a consequence, one daughter cell receives a Notch
signal while the other does not, causing the two cells to adopt different fates. (c) CSL-dependent Notch signalling has also been shown to play a
role in the formation of a boundary (orange cells) between two different populations of cells (green and blue cells). In this situation, Notch signalling
(arrows) is restricted to the cells at the interface between the two populations of cells, causing them to adopt a boundary cell fate.72
may lead to a stronger and longer lasting CSL-dependent
signal. On the other hand, Notch mutants have been iso-
lated in Drosophila that encode similarly truncated pro-
teins [18], and careful analysis indicates that their
phenotype is due to increased Deltex-dependent sig-
nalling. The occurrence of this class of mutation in virus-
induced lymphomas therefore suggests that unregulated
Notch signalling via Deltex may also contribute to tumour
development.
A role for unregulated Notch signalling has also been pro-
posed in cervical cancer, largely because intense cyto-
plasmic and nuclear staining of Notch1 and Notch2
proteins has been observed in a majority of early stage
cervical tumours [40]. Recent experiments with a human
keratinocyte cell line, HaCaT, indicate that Notch sig-
nalling activates the phosphatidylinositol-3-kinase/protein
kinase B signalling pathway and leads to increased resis-
tance to anoikis [41]. In addition, HaCaT cells expressing
the human papillomavirus (HPV) proteins E6 and E7
become transformed if Notch signalling is activated at the
same time. Cooperation between HPV proteins and Notch
signalling may thus lead to tumour initiation within the cer-
vical epithelium. However, a survey of HPV-induced inva-
sive cervical cancers and of established, malignant,
HPV-positive cervical cancer cell lines found that Notch1
levels fall in late stage tumours [42]. This fall coincided
with a rise in the expression of the E6 and E7 proteins,
which is associated with neoplastic transformation. The
results of this study indicate that Notch1 signalling
represses E6 and E7 expression by suppressing the activ-
ity of the AP-1 transcription factor through upregulation of
Fra-1 and suppression of c-Fos expression. Interestingly,
this signalling is likely to occur through a CBF1-indepen-
dent pathway as the repression of E6 and E7 expression
is not affected by overexpressing a dominant-negative
CBF1 protein. This suggests that a fall in Notch1 sig-
nalling may be necessary for progression of HPV-induced
cervical tumours to later stages.
In cancers of many other tissues, the potential role of
Notch signalling in tumour formation has not been exten-
sively studied. However, overexpression of Notch pathway
components has been observed in renal cell carcinomas
[43], head and neck squamous cell carcinomas [44],
endometrial cancer [45] and neuroblastomas [46]. In addi-
tion, activation of the Notch CSL signalling pathway
appears to be mimicked during Epstein–Barr virus [47]
and adenovirus infection [48]. Both viruses produce a
protein that can interact with CSL proteins: Epstein–Barr
virus nuclear antigen 2 in Epstein–Barr virus, and 13SE1A
in adenovirus. Interaction of Epstein–Barr virus nuclear
antigen 2 and 13SE1A with CSL proteins, like the effect
of the Notch intracellular domain, converts the CSL pro-
teins from transcriptional repressors to transcriptional acti-
vators. By analogy with the oncoproteins of DNA tumour
viruses that subvert the key cell-cycle regulators RB and
p53, these data suggest that activation of Notch signalling
may be important for viral replication and may play an
essential role in the immortalisation of cells by Epstein–
Barr virus and adenovirus.
What is the mechanism by which Notch
signalling contributes to tumour formation?
Altogether these data suggest a frequent role for Notch
signalling in human cancer in much the same way as has
recently become clear for Wnt signalling [49]. This raises
the question of how unregulated Notch signalling might
lead to tumour formation. Unlike components of the cell-
cycle machinery or DNA repair proteins, aberrant Notch
signalling does not obviously cause unregulated cell prolif-
eration or genetic alterations associated with tumour pro-
gression. On the other hand, it can alter the
developmental state of a cell and consequently maintain
cells in a proliferative or undifferentiated fate.
Experiments examining the mechanism for T-cell lymphoma
development in mice expressing an activated Notch3
protein under the control of the lck promoter strongly
support this idea [32,50]. During normal thymocyte devel-
opment, Notch3 is expressed at the transition between the
CD4–CD8– double-negative and the CD4+CD8+ double-
positive stages; its expression drops markedly after this.
When Notch3 signalling is activated in transgenic animals,
thymocytes fail to differentiate into CD4+CD8+ cells and
remain as CD4–CD8– cells. This suggests that Notch3 sig-
nalling prevents thymocytes from making this transition in
cell fate [32]. As a consequence of this maintenance of the
CD4–CD8– cell fate, pre T-cell receptor signalling is sus-
tained in the thymocytes of the Notch3 transgenic mice.
Since pre T-cell receptor signalling causes both thymocyte
survival and proliferation, constitutive signalling through this
pathway may be responsible for lymphoma development.
This notion has been confirmed by the failure of lymphomas
to develop in Notch3 transgenic mice in which pre T-cell
receptor signalling is abolished [50]. It is thus the change
in cell fate caused by Notch3 signalling that leads ulti-
mately to T-cell lymphoma.
Within the cervical epithelium, Notch signalling and the
HPV E6 and E7 proteins are thought to cooperate to
permit anchorage-independent growth [41], and thus to
initiate tumour formation. Changes in cell fate may also
play a role, however, as Notch signalling causes cells to
differentiate during normal epithelial development [51,52].
HPV replicates within the differentiated cells and therefore
its survival is dependent upon their continued differentia-
tion [42]. The increased Notch signalling observed in early
stage cervical tumours ensures continued differentiation of
the tissue and may also lead to increased numbers of dif-
ferentiated cells. Furthermore, Notch signalling will sup-
press E6 and E7 expression. This will limit viral replication
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and prevent destructive lysis of host cells. An increase in
Notch signalling will thus help to maintain a HPV infection.
If the mechanism of tumour formation in response to con-
stitutive Notch signalling is indeed due to changes in cell
fate decisions, there may be examples in which aberrant
signalling causes cells to adopt a nonproliferative cell fate
and, hence, does not lead to tumour formation. This possi-
bility may explain recent experiments using small cell lung
cancer cell lines [53]. In these experiments, the expression
of active forms of Notch1 and Notch2 led to growth arrest
and blocked the expression of Mash1, a transcription factor
required for these cells to adopt their neuroendocrine fate.
A role for Notch in murine mammary gland
development and tumourigenesis
The first indication that Notch signalling might play a role
in normal and neoplastic development of the mammary
gland came from the characterisation of a common inser-
tion site for the mouse mammary tumour virus in Czech II
mice [54]. In 20% of these tumours, the mouse mammary
tumour virus provirus was inserted within the Notch4/int-3
locus. Since then, similar mouse mammary tumour virus
insertions into Notch1 have been described [55]. At both
loci, insertion of the provirus leads to expression of a
Notch protein that consists of the transmembrane and
intracellular domains only, again suggesting that unregu-
lated Notch signalling leads to tumour formation.
To test this directly, transgenic mice were generated in
which an activated Notch4 allele was expressed in the
mammary gland [56–58]. In these animals, the mammary
epithelium failed to branch or to penetrate the mammary fat
pad, secretory lobules did not develop during pregnancy,
and poorly differentiated mammary adenocarcinomas
developed within 7 months. Furthermore, the epithelial cells
in the virgin gland showed morphological features similar to
cap cells, the proposed epithelial stem cells found at the
ends of ducts. In addition, most cells failed to express
casein during pregnancy, suggesting that the alveolar
epithelial cells were unable to differentiate correctly.
The effects of Notch4 have also been studied in TAC-2
cells, a mammary cell system that can form ductal struc-
tures when grown in a collagen matrix. Expression of an
activated  Notch4 allele in these cells prevented ductal
branching in response to hepatocyte growth factor (HGF)
and transforming growth factor beta (TGF-β), and induced
an invasive phenotype [59,60]. Taken together, these
results suggest that Notch signalling may regulate ductal
branching during normal mammary gland development
and that unregulated Notch signalling prevents terminal
differentiation of mammary epithelial cells. Aberrant Notch
signalling may thus maintain the epithelial cells in a prolif-
erative cell fate that leads to extensive ductal dysplasia
and an associated risk of progression to carcinoma.
Notch signalling and human breast cancer
The involvement of Notch signalling in murine mammary
tumourigenesis and its potential general role in human
cancer clearly raise the possibility that aberrant Notch sig-
nalling might play a role in human breast cancer. Currently,
however, there is very little direct evidence of this. The rele-
vant published data are largely restricted to three expression
studies. One of these studies examined Notch4 expression
in several different tumour cell lines [61], while the others
examined Notch1 and Notch4 expression in normal breast
tissue and ductal carcinoma in situ [62], and Notch1 expres-
sion in breast cancers that overexpress H-ras [63].
In the first study, an mRNA transcript encoding the intra-
cellular domain of Notch4 was detected in several tumour
cell lines, including the breast cancer lines BT474 and
Hs578T [61]. Importantly, expression of this activated
form of Notch4 in the breast epithelial cell line MCF 10A
enabled the cells to grow in soft agar, indicating that the
transcript had transforming potential. Interestingly, the
Notch4 mRNA isolated encodes an intracellular Notch4
protein that lacks the RAM23 domain required for the
interaction with CBF1. This raises the possibility that the
transformation of MCF 10A by this protein is due to
Deltex-dependent Notch signalling. It should be noted,
however, that Notch1 forms lacking the RAM23 domain
can interact with CBF1 and activate a CBF1-dependent
promoter in the presence of the transcriptional coactivator
Mastermind [34]. Furthermore, a deletion analysis of the
Notch1 protein indicated that only Notch1 proteins able to
activate CSL signalling can transform the murine
mammary epithelial cell line HC11 [55].
The survey of Notch1 and Notch4 expression in normal
breast tissue and ductal carcinoma in situ indicated that
expression of neither protein was detectable in normal
tissue but that one or both proteins were expressed in the
majority of ductal carcinoma in situ lesions [62]. In addi-
tion, Notch1 overexpression was observed in breast
cancers that overexpress H-ras [63]. Finally, it has recently
been shown that reducing the expression of the DSL
ligand Jagged 2 in the breast cancer cell lines MCF7 and
T47D induced caspase activity, suggesting that Notch
signalling prevents apoptosis in these cells [64].
Conclusion
There is strong evidence to date to link unregulated Notch
signalling with T-cell acute lymphoblastic leukaemia in both
humans and mice, and with mammary tumourigenesis in
mice. It is probable that Notch signalling can play a general
role in tumour development in many different tissues by
causing cells to adopt a proliferative cell fate. The initial
results described suggest that unregulated Notch sig-
nalling may also play a role in human breast cancer.
However, there is now a need to examine systematically
whether aberrant Notch signalling occurs in breast cancer.
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First, it will be important to determine whether rearrange-
ments or mutations occur at Notch loci that lead to
expression of activated Notch proteins in breast cancer.
However, while Notch signalling is activated by such
rearrangements in lymphomas and murine mammary
tumours, it is entirely possible that other mechanisms of
Notch signalling activation pertain to breast cancer. It may
thus be necessary to look for either the aberrant activation
of target genes of the Notch signalling pathway or for
nuclear localisation of the NICD fragment. It may also be
necessary to examine activation of the Notch signalling
pathway at different stages in tumour progression, as this
may vary as observed in cervical cancer.
Second, the effects of Notch signalling on mammary
epithelial cell fate, proliferation and survival remain to be
established, along with the target genes that regulate
these effects.
Third, interactions between the Notch and Wnt signalling
pathways during mammary gland development and tumouri-
genesis should be investigated. Constitutive signalling
through each pathway has been linked to the development
of tumours in the murine mammary gland, yet the interaction
between the two pathways appears antagonistic.
Finally, it will also be important to determine which effects
of Notch in mammary development or tumourigenesis are
due to CSL-dependent signalling and which effects are
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